Mark B Pepys

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8432822/publications.pdf

Version: 2024-02-01

136 papers	30,890 citations	15504 65 h-index	11607 135 g-index
137 all docs	137 docs citations	137 times ranked	28072 citing authors

#	Article	IF	Citations
1	Transthyretin amyloidosis: new answers but many questions. Journal of Internal Medicine, 2021, 289, 933-935.	6.0	0
2	C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target?. European Heart Journal, 2021, 42, 2280-2283.	2.2	24
3	Dementia in the older population is associated with neocortex content of serum amyloid P component. Brain Communications, 2021, 3, fcab225.	3.3	5
4	Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. Nature Communications, 2021, 12, 7112.	12.8	13
5	Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils. Journal of Biological Chemistry, 2020, 295, 11379-11387.	3.4	12
6	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes. Journal of Medicinal Chemistry, 2019, 62, 8274-8283.	6.4	25
7	Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Science Translational Medicine, 2018, 10, .	12.4	94
8	The Pentraxins 1975â€“2018: Serendipity, Diagnostics and Drugs. Frontiers in Immunology, 2018, 9, 2382.	4.8	49
9	Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1. PLoS ONE, 2018, 13, e0197299.	2.5	13
10	Plasminogen activation triggers transthyretin amyloidogenesis in vitro. Journal of Biological Chemistry, 2018, 293, 14192-14199.	3.4	68
11	Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 5-6.	3.0	2
12	Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies. Journal of Proteomics, 2017, 165, 113-118.	2.4	14
13	Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular AÎ² amyloid depositsin vivo. Open Biology, 2016, 6, 150202.	3.6	21
14	A novel mechanoâ€enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Molecular Medicine, 2015, 7, 1337-1349.	6.9	109
15	Multinucleated Giant Cells Are Specialized for Complement-Mediated Phagocytosis and Large Target Destruction. Cell Reports, 2015, 13, 1937-1948.	6.4	123
16	Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. New England Journal of Medicine, 2015, 373, 1106-1114.	27.0	304
17	Bifunctional crosslinking ligands for transthyretin. Open Biology, 2015, 5, 150105.	3.6	2
18	Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP). Blood, 2015, 126, 1836-1836.	1.4	4

#	Article	IF	Citations
19	Infusion of Pharmaceutical-Grade Natural Human C-Reactive Protein Is Not Proinflammatory in Healthy Adult Human Volunteers. Circulation Research, 2014, 114, 672-676.	4.5	63
20	Attention to Detail in the Selection of Words in Epidemiologic Research Reports. American Journal of Epidemiology, 2014, 179, 795-796.	3.4	2
21	Protection of Human Podocytes from Shiga Toxin 2-Induced Phosphorylation of Mitogen-Activated Protein Kinases and Apoptosis by Human Serum Amyloid P Component. Infection and Immunity, 2014, 82, 1872-1879.	2.2	22
22	Interaction of serum amyloid P component with hexanoyl bis(<scp>D</scp>-proline) (CPHPC). Acta Crystallographica Section D: Biological Crystallography, 2014, 70, 2232-2240.	2.5	11
23	Câ€reactive protein is essential for innate resistance to pneumococcal infection. Immunology, 2014, 142, 414-420.	4.4	51
24	Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1539-1544.	7.1	91
25	Targeted treatment for amyloidosis. Israel Medical Association Journal, 2014, 16, 277-80.	0.1	5
26	Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay. Journal of Immunological Methods, 2013, 390, 63-73.	1.4	33
27	Pathogenetic mechanisms of amyloid A amyloidosis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16115-16120.	7.1	79
28	Structure, Folding Dynamics, and Amyloidogenesis of D76N Î²2-Microglobulin. Journal of Biological Chemistry, 2013, 288, 30917-30930.	3.4	80
29	Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 93-98.	3.0	7
30	C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. New England Journal of Medicine, 2012, 367, 1310-1320.	27.0	909
31	Hereditary Systemic Amyloidosis Due to Asp76Asn Variant Î²₂-Microglobulin. New England Journal of Medicine, 2012, 366, 2276-2283.	27.0	172
32	Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and Câ€reactive protein, for clinical use. Journal of Immunological Methods, 2012, 384, 92-102.	1.4	32
33	Immunoradiometric assay for human serum amyloid P component. Journal of Immunological Methods, 2011, 371, 18-24.	1.4	6
34	Structural basis of ligand specificity in the human pentraxins, Câ€reactive protein and serum amyloid P component. Journal of Molecular Recognition, 2011, 24, 371-377.	2.1	34
35	Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ: British Medical Journal, 2011, 342, d548-d548.	2.3	530
36	Lack of effect of a single injection of human Câ€reactive protein on murine lupus or nephrotoxic nephritis. Arthritis and Rheumatism, 2010, 62, 245-249.	6.7	17

#	Article	IF	Citations
37	Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. British Journal of Haematology, 2010, 148, 760-767.	2.5	106
38	Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 2010, 468, 93-97.	27.8	290
39	Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20483-20488.	7.1	55
40	C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet, The, 2010, 375, 132-140.	13.7	1,946
41	Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7619-7623.	7.1	63
42	C-Reactive Protein and Coronary Disease. Circulation, 2009, 120, 2036-2039.	1.6	49
43	A molecular correlate of clinicopathology in transthyretin amyloidosis. Journal of Pathology, 2009, 217, 1-3.	4.5	16
44	Jack Pepys (May 15, 1914â€“September 9, 1996): A personal recollection. Journal of Allergy and Clinical Immunology, 2009, 123, 718-720.	2.9	1
45	C-reactive protein is neither a marker nor a mediator of atherosclerosis. Nature Clinical Practice Nephrology, 2008, 4, 234-235.	2.0	29
46	Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoEâ^'/â^' mice. Atherosclerosis, 2008, 196, 248-255.	0.8	96
47	Complement Factor H Binds to Denatured Rather than to Native Pentameric C-reactive Protein. Journal of Biological Chemistry, 2008, 283, 30451-30460.	3.4	82
48	Science and serendipity. Clinical Medicine, 2007, 7, 562-578.	1.9	27
49	Human plasma fibrinogen is synthesized in the liver. Blood, 2007, 109, 1971-1974.	1.4	251
50	Î²-Edge Interactions in a Pentadecameric Human Antibody VÎº Domain. Journal of Molecular Biology, 2007, 367, 603-608.	4.2	13
51	Normal circulating serum amyloid P component concentration in systemic sclerosis. Arthritis and Rheumatism, 2007, 56, 2013-2017.	6.7	14
52	Is leptin an important physiological regulator of CRP?. Nature Medicine, 2007, 13, 17-18.	30.7	14
53	C-reactive protein and cardiovascular disease: Weighing the evidence. Current Cardiovascular Risk Reports, 2007, 1, 72-79.	2.0	1
54	Amyloidosis. Annual Review of Medicine, 2006, 57, 223-241.	12.2	557

#	Article	IF	Citations
55	Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 2006, 107, 1227-1229.	1.4	113
56	Targeting C-reactive protein for the treatment of cardiovascular disease. Nature, 2006, 440, 1217-1221.	27.8	621
57	C-reactive protein and cardiovascular disease: Weighing the evidence. Current Atherosclerosis Reports, 2006, 8, 421-428.	4.8	75
58	Human Serum Amyloid P Component Protects againstEscherichia coliO157:H7 Shiga Toxin 2 In Vivo: Therapeutic Implications for Hemolyticâ€Uremic Syndrome. Journal of Infectious Diseases, 2006, 193, 1120-1124.	4.0	48
59	CRP or not CRP? That Is the Question. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1091-1094.	2.4	98
60	Inflammation and Endothelial Function. Circulation, 2005, 111, 1530-1536.	1.6	175
61	Proinflammatory Effects of Bacterial Recombinant Human C-Reactive Protein Are Caused by Contamination With Bacterial Products, Not by C-Reactive Protein Itself. Circulation Research, 2005, 97, e97-103.	4.5	121
62	Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8309-8314.	7.1	194
63	Genetic Effects on Baseline Values of C-Reactive Protein and Serum Amyloid A Protein: A Comparison of Monozygotic and Dizygotic Twins. Clinical Chemistry, 2004, 50, 130-134.	3.2	139
64	Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?. Immunology, 2004, 112, 255-264.	4.4	63
65	Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice. Immunology, 2004, 112, 250-254.	4.4	2
66	Human C-Reactive Protein Increases Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Adult Rats. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 1214-1218.	4.3	137
67	Obesity Is an Important Determinant of Baseline Serum C-Reactive Protein Concentration in Monozygotic Twins, Independent of Genetic Influences. Circulation, 2004, 109, 3022-3028.	1.6	168
68	C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease. New England Journal of Medicine, 2004, 350, 1387-1397.	27.0	2,608
69	Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. British Journal of Haematology, 2003, 122, 78-84.	2.5	370
70	MHC typing in variant Creutzfeldt-Jakob disease. Lancet, The, 2003, 361, 487-489.	13.7	24
71	Markers of inflammation in women on different hormone replacement therapies. Annals of Medicine, 2003, 35, 353-361.	3.8	27
72	Refinement of the Association of Serum C-reactive Protein Concentration and Coronary Heart Disease Risk by Correction for Within-Subject Variation over Time: The MONICA Augsburg Studies, 1984 and 1987. American Journal of Epidemiology, 2003, 158, 357-364.	3.4	111

#	Article	IF	Citations
73	Determination of C-Reactive Protein: Comparison of Three High-Sensitivity Immunoassays. Clinical Chemistry, 2003, 49, 1691-1695.	3.2	30
74	Human C-Reactive Protein Does Not Protect against Acute Lipopolysaccharide Challenge in Mice. Journal of Immunology, 2003, 171, 6046-6051.	0.8	33
75	Dame Sheila Patricia Violet Sherlock. 31 March 1918 â€“ 30 December 2001 Elected FRS 2001. Biographical Memoirs of Fellows of the Royal Society, 2003, 49, 475-493.	0.1	2
76	C-reactive protein: a critical update. Journal of Clinical Investigation, 2003, 111, 1805-1812.	8.2	1,673
77	C-reactive protein: a critical update. Journal of Clinical Investigation, 2003, 111, 1805-1812.	8.2	2,941
78	Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis. New England Journal of Medicine, 2002, 346, 1786-1791.	27.0	621
79	Production of Granulocyte Colony-Stimulating Factor in the Nonspecific Acute Phase Response Enhances Host Resistance to Bacterial Infection. Journal of Immunology, 2002, 169, 913-919.	0.8	47
80	C-Reactive Protein Risk Prediction: Low Specificity, High Sensitivity. Annals of Internal Medicine, 2002, 136, 550.	3.9	21
81	Influenza virus infection is not affected by serum amyloid P component. Molecular Medicine, 2002, 8, 9-15.	4.4	9
82	Lack of seasonal variation in C-reactive protein. Clinical Chemistry, 2002, 48, 575-7.	3.2	10
83	Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy. Journal of Molecular Biology, 2001, 311, 241-247.	4.2	110
84	Effect of alcohol consumption on systemic markers of inflammation. Lancet, The, 2001, 357, 763-767.	13.7	496
85	Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet, The, 2001, 358, 24-29.	13.7	520
86	Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nature Medicine, 2001, 7, 485-487.	30.7	206
87	C-Reactive Protein, Insulin Resistance, Central Obesity, and Coronary Heart Disease Risk in Indian Asians From the United Kingdom Compared With European Whites. Circulation, 2001, 104, 145-150.	1.6	382
88	LIVER TRANSPLANTATION FOR END STAGE HEPATIC AMYLOIDOSIS.. Transplantation, 2000, 69, S139.	1.0	0
89	Immunoradiometric Assay of Circulating C-Reactive Protein: Age-related Values in the Adult General Population. Clinical Chemistry, 2000, 46, 934-938.	3.2	218
90	The protofilament substructure of amyloid fibrils11Edited by F. E. Cohen. Journal of Molecular Biology, 2000, 300, 1033-1039.	4.2	332

#	Article	IF	Citations
91	Molecular chaperone properties of serum amyloid P component. FEBS Letters, 2000, 473, 199-202.	2.8	49
92	Infection With Helicobacter pylori Is Not a Major Independent Risk Factor for Stable Coronary Heart Disease. Circulation, 1999, 100, 2326-2331.	1.6	83
93	The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure, 1999, 7, 169-177.	3.3	656
94	Acute phase response and evolution of familial Mediter ranean fever. Lancet, The, 1999, 353, 1415.	13.7	160
95	C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men. Circulation, 1999, 99, 237-242.	1.6	1,672
96	Enhanced inflammatory response in patients with preinfarction unstable angina. Journal of the American College of Cardiology, 1999, 34, 1696-1703.	2.8	144
97	Hereditary renal amyloidosis associated with variant lysozyme in a large English family. Nephrology Dialysis Transplantation, 1999, 14, 2639-2644.	0.7	72
98	Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 709-713.	6.4	68
99	Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney International, 1998, 53, 276-281.	5.2	70
100	SAA₁alleles as risk factors in reactive systemic AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 262-265.	3.0	104
101	Enhanced Inflammatory Response to Coronary Angioplasty in Patients With Severe Unstable Angina. Circulation, 1998, 98, 2370-2376.	1.6	292
102	Interleukin 6 Influences Germinal Center Development and Antibody Production via a Contribution of C3 Complement Component. Journal of Experimental Medicine, 1998, 188, 1895-1906.	8.5	177
103	Scintigraphy with 123I-Serum Amyloid P Component in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1998, 12, 208-210.	1.3	21
104	Rapid Automated High Sensitivity Enzyme Immunoassay of C-Reactive Protein. Clinical Chemistry, 1998, 44, 1358-1361.	3.2	123
105	DOMINO HEPATIC TRANSPLANTATION USING THE LIVER FROM A PATIENT WITH FAMILIAL AMYLOID POLYNEUROPATHY. Transplantation, 1998, 65, 1496-1498.	1.0	55
106	Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. Age and Ageing, 1997, 26, 153-158.	1.6	57
107	Amyloid and the Gut. Digestive Diseases, 1997, 15, 155-171.	1.9	36
108	Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP. Journal of Molecular Biology, 1997, 269, 570-578.	4.2	43

#	Article	IF	Citations
109	Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses 1 1Edited by R. Huber. Journal of Molecular Biology, 1997, 272, 408-422.	4.2	113
110	Common core structure of amyloid fibrils by synchrotron X-ray diffraction 1 1Edited by F. E. Cohen. Journal of Molecular Biology, 1997, 273, 729-739.	4.2	1,590
111	The MHC class II-restricted T cell response of C57BL/6 mice to human C-reactive protein: Homology to self and the selection of T cell epitopes and T cell receptors. Molecular Immunology, 1997, 34, 115-124.	2.2	8
112	Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nature Medicine, 1997, 3, 855-859.	30.7	239
113	Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature, 1997, 385, 787-793.	27.8	1,061
114	Echocardiographic assessment of cardiac involvement in systemic AL amyloidosis in relation to whole body amyloid load measured by serum amyloid P component (SAP) clearance. American Journal of Cardiology, 1997, 80, 1104-1108.	1.6	10
115	AMYLOIDOSIS: A REVIEW OF RECENT DIAGNOSTIC AND THERAPEUTIC DEVELOPMENTS. British Journal of Haematology, 1997, 99, 245-256.	2.5	166
116	Three dimensional structure of human C-reactive protein. Nature Structural and Molecular Biology, 1996, 3, 346-354.	8.2	308
117	Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney International, 1996, 50, 282-289.	5.2	56
118	Plasma Protein Acute-Phase Response in Unstable Angina Is Not Induced by Ischemic Injury. Circulation, 1996, 94, 2373-2380.	1.6	134
119	Tolerance and immunity to the inducible self antigen C-reactive protein in transgenic mice. European Journal of Immunology, 1995, 25, 3489-3495.	2.9	18
120	Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1995, 2, 163-166.	3.0	7
121	The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina. New England Journal of Medicine, 1994, 331, 417-424.	27.0	2,159
122	Structure of pentameric human serum amyloid P component. Nature, 1994, 367, 338-345.	27.8	471
123	Comparative analyses of pentraxins: implications for protomer assembly and ligand binding. Structure, 1994, 2, 1017-1027.	3.3	96
124	Molecular characterization of Limulus polyphemus C-reactive protein. I. Subunit composition. FEBS Journal, 1993, 214, 91-97.	0.2	42
125	Molecular characterization of Limulus Polyphemus C-reactive protein. II. Asparagine-linked oligosaccharides. FEBS Journal, 1993, 214, 99-110.	0.2	13
126	Serum amyloid P component in chronic renal failure and dialysis. Clinica Chimica Acta, 1991, 200, 191-199.	1.1	79

#	Article	IF	Citations
127	Tissue Vitronectin in Normal Adult Human Dermis Is Non-Covalently Bound to Elastic Tissue. Journal of Investigative Dermatology, 1991, 96, 747-753.	0.7	22
128	Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAPâ€met³⁰). Clinical Genetics, 1991, 40, 242-246.	2.0	350
129	Evaluation of Systemic Amyloidosis by Scintigraphy with¹²³I-Labeled Serum Amyloid P Component. New England Journal of Medicine, 1990, 323, 508-513.	27.0	497
130	Tissue Amyloid P Component in Normal Human Dermis is Non-covalently Associated with Elastic Fiber Microfibrils. Journal of Investigative Dermatology, 1989, 92, 53-58.	0.7	21
131	Amyloid P Component Binds to Keratin Bodies in Human Skin and to Isolated Keratin Filament Aggregates In Vitro. Journal of Investigative Dermatology, 1988, 91, 22-28.	0.7	35
132	Imaging of experimental amyloidosis with131i-labeled serum amyloid p component. Arthritis and Rheumatism, 1987, 30, 1303-1306.	6.7	26
133	Murine type II collagen arthritis: Association of an acute-phase response with clinical course. Arthritis and Rheumatism, 1986, 29, 1131-1138.	6.7	12
134	Correlation of disease activity in systemic vasculitis with serum C-reactive protein measurement. A prospective study of thirty-eight patients. European Journal of Clinical Investigation, 1985, 15, 89-94.	3.4	15
135	Serum C-reactive protein levels in the management of infection in acute leukaemia. European Journal of Cancer & Clinical Oncology, 1984, 20, 319-325.	0.7	35
136	Immunohistochemical Studies of Amyloid P Component Distribution in Normal Human Skin. Journal of Investigative Dermatology, 1983, 80, 86-90.	0.7	43